Suppr超能文献

[¹⁸F]氟替美莫在野生型啮齿动物中的药代动力学及其与阿尔茨海默病小鼠模型中β淀粉样蛋白沉积的结合。

Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease.

机构信息

MediCity/PET Preclinical Laboratory, Turku PET Centre, University of Turku, Tykistökatu 6A, FI-20520 Turku, Finland.

出版信息

Eur J Nucl Med Mol Imaging. 2012 Nov;39(11):1784-95. doi: 10.1007/s00259-012-2178-9. Epub 2012 Jul 17.

Abstract

PURPOSE

The aim of this study was to investigate the potential of [(18)F]flutemetamol as a preclinical PET tracer for imaging β-amyloid (Aβ) deposition by comparing its pharmacokinetics to those of [(11)C]Pittsburgh compound B ([(11)C]PIB) in wild-type Sprague Dawley rats and C57Bl/6N mice. In addition, binding of [(18)F]flutemetamol to Aβ deposits was studied in the Tg2576 transgenic mouse model of Alzheimer's disease.

METHODS

[(18)F]Flutemetamol biodistribution was evaluated using ex vivo PET methods and in vivo PET imaging in wild-type rats and mice. Metabolism and binding of [(11)C]PIB and [(18)F]flutemetamol to plasma proteins were analysed using thin-layer chromatography and ultrafiltration methods, respectively. Radiation dose estimates were calculated from rat ex vivo biodistribution data. The binding of [(18)F]flutemetamol to Aβ deposits was also studied using ex vivo and in vitro autoradiography. The location of Aβ deposits in the brain was determined with thioflavine S staining and immunohistochemistry.

RESULTS

The pharmacokinetics of [(18)F]flutemetamol resembled that of [(11)C]PIB in rats and mice. In vivo studies showed that both tracers readily entered the brain, and were excreted via the hepatobiliary pathway in both rats and mice. The metabolism of [(18)F]flutemetamol into radioactive metabolites was faster than that of [(11)C]PIB. [(18)F]Flutemetamol cleared more slowly from the brain than [(11)C]PIB, particularly from white matter, in line with its higher lipophilicity. Effective dose estimates for [(11)C]PIB and [(18)F]flutemetamol were 2.28 and 6.65 μSv/MBq, respectively. Autoradiographs showed [(18)F]flutemetamol binding to fibrillar Aβ deposits in the brain of Tg2576 mice.

CONCLUSION

Based on its pharmacokinetic profile, [(18)F]flutemetamol showed potential as a PET tracer for preclinical imaging. It showed good brain uptake and was bound to Aβ deposits in the brain of Tg2576 mice. However, its high lipophilicity might complicate the analysis of PET data, particularly in small-animal imaging.

摘要

目的

本研究旨在通过比较 [(18)F]flutemetamol 与 [(11)C]Pittsburgh 化合物 B ([(11)C]PIB) 的药代动力学,研究其作为β-淀粉样蛋白 (Aβ) 沉积的临床前 PET 示踪剂的潜力。[(18)F]flutemetamol 在野生型 Sprague Dawley 大鼠和 C57Bl/6N 小鼠中的分布。此外,还研究了 [(18)F]flutemetamol 在阿尔茨海默病转基因小鼠模型 Tg2576 中的结合情况。

方法

采用 ex vivo PET 方法和活体 PET 成像评估 [(18)F]flutemetamol 的生物分布。采用薄层层析法和超滤法分别分析 [(11)C]PIB 和 [(18)F]flutemetamol 与血浆蛋白的结合情况。根据大鼠 ex vivo 生物分布数据计算辐射剂量估计值。采用 ex vivo 和体外放射自显影研究 [(18)F]flutemetamol 与 Aβ 沉积物的结合情况。采用噻唑黄素 S 染色和免疫组织化学法确定脑内 Aβ 沉积物的位置。

结果

[(18)F]flutemetamol 的药代动力学在大鼠和小鼠中类似于 [(11)C]PIB。体内研究表明,两种示踪剂均易进入大脑,并通过大鼠和小鼠的肝胆途径排出。[(18)F]flutemetamol 向放射性代谢物的代谢速度快于 [(11)C]PIB。[(18)F]flutemetamol 从大脑中的清除速度比 [(11)C]PIB 慢,特别是在白质中,与其较高的亲脂性一致。[(11)C]PIB 和 [(18)F]flutemetamol 的有效剂量估计值分别为 2.28 和 6.65 μSv/MBq。放射自显影显示 [(18)F]flutemetamol 与 Tg2576 小鼠脑内纤维状 Aβ 沉积物结合。

结论

根据其药代动力学特征,[(18)F]flutemetamol 有望成为临床前成像的 PET 示踪剂。它显示出良好的脑摄取能力,并与 Tg2576 小鼠脑内的 Aβ 沉积物结合。然而,其高亲脂性可能会使 PET 数据的分析复杂化,尤其是在小动物成像中。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验